J&J booster 85% effective against hospitalization in S. Africa

Thursday, 30. December 2021 13:24

Johnson & Johnson announced on Thursday that the booster shot of its coronavirus vaccine showed 85% effectiveness against hospitalization in South Africa during the dominance of the Omicron variant. The company cited a study that the South African Medical Research Council (SAMRC) carried out among healthcare workers in the country at the same time as Omicron's share in all new cases surged to 98%.

In addition, a study conducted by Beth Israel Deaconess Medical Center (BIDMC) showed that J&J booster shot "generated a 41-fold increase in neutralizing antibody responses and a 5-fold increase in CD8+ T-cells to Omicron by four weeks following the boost" in people who were initially vaccinated with the Pfizer Inc.-BioNTech SE mRNA jab. "Both neutralizing antibodies and CD8+ T-cells were higher four weeks after the boost with the Johnson & Johnson vaccine" compared to Pfizer-BioNTech booster, according to the analysis.

Mathai Mammen, global head of J&J's subsidiary Janssen Research & Development LLC, said that protection and "strong and stable" effectiveness "could be due to the robust T-cell responses" its vaccine induces, adding that "these data suggest that Omicron is not affecting the T-cell responses generated by our vaccine."

Related Links: Johnson & Johnson
Baha Breaking News (BBN) / MS